Clinical Trials Browser

Recurrence, Endometrial Neoplasms

NCT01582191 2025-10-27

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

151 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT00081874 2025-04-27

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Phase 1/2 Completed

29 enrolled

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Clinical Trials

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Pilot Trial for Treatment of Recurrent Glioblastoma

CRAD001NUS175T

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

RADBEV

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer